News
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris
Implied Volatility Surging for Associated BancCorp Stock Options
Investors in Associated Banc-Corp ASB need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 19, 2025 $15 Put had some of the highest implied
Is the Options Market Predicting a Spike in Easterly Government Properties Stock?
Investors in Easterly Government Properties, Inc. DEA need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 19, 2025 $22.50 Put had some of
Higher NII & Fee Income to Aid Huntington Bancshares' Q2 Earnings
Huntington Bancshares Incorporated HBAN is slated to report second-quarter 2025 results on July 18, before the opening bell. The company’s quarterly revenues and earnings are expected to have
Coca-Cola's Bottler Strategy Evolves: What is the Margin Impact?
The Coca-Cola Company KO is steadily reshaping its global bottling footprint through a long-term refranchising strategy that shifts bottling operations to local partners. This asset-light approach
How to Boost Your Portfolio with Top Consumer Discretionary Stocks Set to Beat Earnings
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.
The
How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.
The
How to Boost Your Portfolio with Top Oils and Energy Stocks Set to Beat Earnings
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.
The
Want Better Returns? Don't Ignore These 2 Computer and Technology Stocks Set to Beat Earnings
Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure
These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure
These 2 Utilities Stocks Could Beat Earnings: Why They Should Be on Your Radar
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the
Why Investors Need to Take Advantage of These 2 Computer and Technology Stocks Now
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a
Want Better Returns? Don't Ignore These 2 Basic Materials Stocks Set to Beat Earnings
Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a
ArcelorMittal (MT) Shows Fast-paced Momentum But Is Still a Bargain Stock
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among
Here's What Could Help Brainsway (BWAY) Maintain Its Recent Price Strength
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure
NVDA Greenlight: China H20 Sales Spark 50% Rally Potential
NVIDIA’s (NASDAQ: NVDA) market received a green light to rally that will have far-reaching repercussions. NVIDIA is the largest company globally, with a valuation exceeding $4 trillion, and has
Higher NII & Non-Interest Income to Aid U.S. Bancorp's Q2 Earnings
U.S. Bancorp USB is scheduled to report second-quarter 2025 results on July 17, 2025, before the opening bell. The company is expected to have witnessed year-over-year increases in quarterly
Tesla Q2 Earnings Preview: Will the EV Giant Disappoint Again?
Tesla TSLA is set to release second-quarter 2025 results on July 23, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 40 cents


